FindTrial
Sign In

A comparative analysis of the effectiveness of autologous platelet-rich plasma as a new additive for IVM and IVC

A comparative analysis of the effectiveness of autologous PRP as a new additive for IVM and IVC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008597
Enrollment
200
Registered
2023-07-13
Start date
2022-08-23
Completion date
Unknown
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Maria Fertility Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Among the patient population seeking IVF, patients undergoing immature cycles and patients who have undergone three or more transfers, including previous in vitro fertilization(IVF-ET) cycles and thawed embryo transfer cycles, and have failed to conceive will be recruited.

Exclusion criteria

Exclusion criteria: 1. Patients with uterine adenomyosis. 2. Patients with uterine structural factors such as congenital uterine anomaly. 3. Patients with a history of viral diseases or sexually transmitted diseases, including hepatitis

Design outcomes

Primary

MeasureTime frame
Development, pregnancy, and implantation rates of embryos cultured using PRP.—

Secondary

MeasureTime frame
Age, BMI, AMH, duration of infertility, and endometrial thickness in patients who used PRP.—

Countries

Korea, Republic of

Contacts

Public ContactChang-Seop Hyun

Maria Fertility hospital

cshyun@mariababy.com+82-31-470-7637

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026